A valid prescription requires a telehealth consultation with a licensed provider. No medication is dispensed without clinical evaluation.
CJC-1295 (with DAC)
Long-Acting Drug Affinity Complex GHRH Analog
Compound Specifications
CJC-1295 (with DAC)
Long-Acting Drug Affinity Complex GHRH Analog
CJC-1295 with DAC (Drug Affinity Complex) is an engineered GHRH derivative that bioconjugates with circulating serum albumin, extending its biological half-life to 6-8 days for sustained elevation of basal growth hormone and IGF-1.
Covalent binding to endogenous albumin creates a steady reservoir that continuously stimulates pituitary GHRH receptors, elevating baseline circulating IGF-1.
Documented Therapeutic Benefits
Results may vary. Individual outcomes depend on adherence, baseline health, and other factors.
Subcutaneous injection once or twice weekly per physician direction.
Frequently Asked Clinical Questions
How often is CJC-1295 with DAC dosed?
Due to its albumin-binding Drug Affinity Complex, it has a half-life of roughly 8 days and is typically administered only once or twice per week.